• 1. 福建醫(yī)科大學(xué)附屬第一醫(yī)院中心實(shí)驗(yàn)室( 福州 350005) ;;
  • 2. 福建醫(yī)科大學(xué)附屬第一醫(yī)院病理科;;
  • 3. 福建醫(yī)科大學(xué)附屬第一醫(yī)院腫瘤外科;

目的 探討T細(xì)胞共刺激分子及其亞群在胃癌、大腸癌發(fā)生及預(yù)后中的作用.方法 應(yīng)用流式細(xì)胞術(shù)檢測38例胃癌、42例大腸癌患者和21例健康人(對照組)外周血T細(xì)胞亞群及其共刺激分子CD28的表達(dá).結(jié)果 T細(xì)胞共刺激分子CD28(CD28+CD3+)表達(dá): 胃癌組為(25.80±10.56)%,大腸癌組為(28.95±9.29)%,均明顯高于對照組的(0.82±0.98)%,P＜0.01; 總T細(xì)胞(CD3+)表達(dá): 胃癌組為(53.61±13.84)%,大腸癌組為(55.96±10.68)%,均明顯低于對照組的(72.07±7.83)%,P＜0.01; CD4+ T細(xì)胞(CD4+CD3+)表達(dá): 胃癌組為(29.84±9.71)%,大腸癌組為(33.75±9.04)%,也均明顯低于對照組的(38.79±5.08)%,P＜0.01, P＜0.05; 細(xì)胞毒T細(xì)胞(CTL,CD8+CD28+CD3+)表達(dá): 胃癌組為(1.57±1.99)%,大腸癌組為(1.93±2.61)%,均明顯高于對照組的(0.02±0.04)%,P＜0.01; 胃癌組CD8+抑制性T細(xì)胞(CD8+CD28-CD3+)和CD4/CD8比值明顯低于對照組[(16.06±6.94)% vs (20.56±6.54)%,P＜0.05; (1.10±0.51)% vs (1.36±0.31)%,P＜0.05]; 大腸癌組調(diào)節(jié)性T細(xì)胞(CD4+CD25+CD3+)明顯高于對照組[(19.74±6.89)% vs (13.72±3.08)%, P＜0.01].胃癌組和大腸癌組患者手術(shù)前和手術(shù)后1周外周血T細(xì)胞亞群(除外胃癌組的CD3+細(xì)胞和CD28+CD3-細(xì)胞)的差異無統(tǒng)計(jì)學(xué)意義(P＞0.05). 結(jié)論胃癌和大腸癌患者T細(xì)胞數(shù)量明顯減少,T細(xì)胞共刺激分子CD28表達(dá)增高.胃癌患者CD4+T細(xì)胞顯著減少; 大腸癌患者調(diào)節(jié)性T細(xì)胞顯著增加.

引用本文： 傅冷西,張聲,陳思曾. T 細(xì)胞共刺激分子及其亞群在胃癌和大腸癌組織中表達(dá)的意義. 中國普外基礎(chǔ)與臨床雜志, 2008, 15(1): 51-55. doi: 復(fù)制

版權(quán)信息： ?四川大學(xué)華西醫(yī)院華西期刊社《中國普外基礎(chǔ)與臨床雜志》版權(quán)所有，未經(jīng)授權(quán)不得轉(zhuǎn)載、改編

1. Antony PA,Piccirillo CA,Akpinarli A,et al.CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells[J].J Immunol,2005; 174(5)∶2591.
2. 林學(xué)顏,張玲主編.現(xiàn)代細(xì)胞分子免疫學(xué)[M].第1版.北京:科學(xué)出版社,2003∶384～385.
3. Sakaguchi S,Sakaguchi N,Asano M,et al.Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25).Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases[J].J Immunol,1995; 155(3)∶1151.
4. Chattopadhyay S,Chakraborty NG,Mukherji B.Regulatory T cells and tumor immunity[J].Cancer Immunol Immunother,2005; 54(12)∶1153.
5. 吳靜靜,王俐.CD4+CD25+ 調(diào)節(jié)性T 細(xì)胞及其與腫瘤的關(guān)系[J].國外醫(yī)學(xué)·腫瘤學(xué)分冊,2004; 31(7)∶496.
6. 李曉,汪輝.CD4+CD25+調(diào)節(jié)性T細(xì)胞和腫瘤免疫[J].國外醫(yī)學(xué)·免疫學(xué)分冊,2003; 26(6)∶326.
7. Yu P,Lee Y,Liu W,et al.Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors[J].J Exp Med,2005; 201(5)∶779.
8. Seo N,Hayakawa S,Takigawa M,et al.Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity[J].Immunology,2001; 103(4)∶449.
9. 劉莉,丁乾,姚軍霞,等.結(jié)直腸癌患者外周血CD4+CD25high調(diào)節(jié)性T細(xì)胞分析[J].中華腫瘤防治雜志,2007; 14(2)∶110.
10. 任秀紅,劉莉,劉平平,等.惡性腫瘤患者T細(xì)胞亞群變化及其與腫瘤分期的關(guān)系[J].第三軍醫(yī)大學(xué)學(xué)報(bào),2006; 28(18)∶1906.
11. Ercolini AM,Ladle BH,Manning EA,et al.Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response[J].J Exp Med,2005; 201(10)∶1591.
12. Sasada T,Kimura M,Yoshida Y,et al.CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies:possible involvement of regulatory T cells in disease progression[J].Cancer,2003; 98(5)∶1089.
13. Scotto L,Naiyer AJ,Galluzzo S,et al.Overlap between molecular markers expressed by naturally occurring CD4+CD25+ regulatory T cells and antigen specific CD4+CD25+ and CD8+CD28-T suppressor cells[J].Hum Immunol,2004; 65(11)∶1297.
14. 金伯泉主編.細(xì)胞和分子免疫學(xué)[M].第2版.北京:科學(xué)出版社,2001∶17.
15. 林文棠,朱平主編.實(shí)用臨床免疫學(xué)[M].第1版.西安:第四軍醫(yī)大學(xué)出版社,2003∶166～168.
16. 李曉,徐蘭波.共刺激分子在腫瘤免疫治療中的應(yīng)用[J].國外醫(yī)學(xué)·腫瘤學(xué)分冊,2005; 32(1)∶25.
17. 張曉膺,鄭世營,趙軍,等.外源性B7-1基因誘導(dǎo)抗肺癌主動(dòng)免疫的實(shí)驗(yàn)研究[J].中華實(shí)驗(yàn)外科雜志,2005; 22(7)∶884.
18. 張清媛,李殿俊,王志華,等.B7-1基因修飾的腫瘤細(xì)胞疫苗抗腫瘤的實(shí)驗(yàn)研究[J].中國免疫學(xué)雜志,2001; 17(5)∶249.
19. 陳農(nóng).胃癌患者手術(shù)前后外周血自然殺傷細(xì)胞和T淋巴細(xì)胞亞群的變化[J].浙江醫(yī)學(xué),2002; 24(10)∶579.
20. 董暉,王朝杰.結(jié)直腸癌患者免疫狀況與腫瘤分期的關(guān)系[J].國外醫(yī)學(xué)·放射醫(yī)學(xué)核醫(yī)學(xué)分冊,2005; 29(3)∶115.
21. 陳榮,蔡景理,周斌,等.免疫增強(qiáng)型腸內(nèi)營養(yǎng)制劑對結(jié)直腸腫瘤術(shù)后機(jī)體免疫的影響[J].中華胃腸外科雜志,2005; 8(4)∶328.
  1. 1. Antony PA,Piccirillo CA,Akpinarli A,et al.CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells[J].J Immunol,2005; 174(5)∶2591.
  2. 2. 林學(xué)顏,張玲主編.現(xiàn)代細(xì)胞分子免疫學(xué)[M].第1版.北京:科學(xué)出版社,2003∶384～385.
  3. 3. Sakaguchi S,Sakaguchi N,Asano M,et al.Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25).Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases[J].J Immunol,1995; 155(3)∶1151.
  4. 4. Chattopadhyay S,Chakraborty NG,Mukherji B.Regulatory T cells and tumor immunity[J].Cancer Immunol Immunother,2005; 54(12)∶1153.
  5. 5. 吳靜靜,王俐.CD4+CD25+ 調(diào)節(jié)性T 細(xì)胞及其與腫瘤的關(guān)系[J].國外醫(yī)學(xué)·腫瘤學(xué)分冊,2004; 31(7)∶496.
  6. 6. 李曉,汪輝.CD4+CD25+調(diào)節(jié)性T細(xì)胞和腫瘤免疫[J].國外醫(yī)學(xué)·免疫學(xué)分冊,2003; 26(6)∶326.
  7. 7. Yu P,Lee Y,Liu W,et al.Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors[J].J Exp Med,2005; 201(5)∶779.
  8. 8. Seo N,Hayakawa S,Takigawa M,et al.Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity[J].Immunology,2001; 103(4)∶449.
  9. 9. 劉莉,丁乾,姚軍霞,等.結(jié)直腸癌患者外周血CD4+CD25high調(diào)節(jié)性T細(xì)胞分析[J].中華腫瘤防治雜志,2007; 14(2)∶110.
  10. 10. 任秀紅,劉莉,劉平平,等.惡性腫瘤患者T細(xì)胞亞群變化及其與腫瘤分期的關(guān)系[J].第三軍醫(yī)大學(xué)學(xué)報(bào),2006; 28(18)∶1906.
  11. 11. Ercolini AM,Ladle BH,Manning EA,et al.Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response[J].J Exp Med,2005; 201(10)∶1591.
  12. 12. Sasada T,Kimura M,Yoshida Y,et al.CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies:possible involvement of regulatory T cells in disease progression[J].Cancer,2003; 98(5)∶1089.
  13. 13. Scotto L,Naiyer AJ,Galluzzo S,et al.Overlap between molecular markers expressed by naturally occurring CD4+CD25+ regulatory T cells and antigen specific CD4+CD25+ and CD8+CD28-T suppressor cells[J].Hum Immunol,2004; 65(11)∶1297.
  14. 14. 金伯泉主編.細(xì)胞和分子免疫學(xué)[M].第2版.北京:科學(xué)出版社,2001∶17.
  15. 15. 林文棠,朱平主編.實(shí)用臨床免疫學(xué)[M].第1版.西安:第四軍醫(yī)大學(xué)出版社,2003∶166～168.
  16. 16. 李曉,徐蘭波.共刺激分子在腫瘤免疫治療中的應(yīng)用[J].國外醫(yī)學(xué)·腫瘤學(xué)分冊,2005; 32(1)∶25.
  17. 17. 張曉膺,鄭世營,趙軍,等.外源性B7-1基因誘導(dǎo)抗肺癌主動(dòng)免疫的實(shí)驗(yàn)研究[J].中華實(shí)驗(yàn)外科雜志,2005; 22(7)∶884.
  18. 18. 張清媛,李殿俊,王志華,等.B7-1基因修飾的腫瘤細(xì)胞疫苗抗腫瘤的實(shí)驗(yàn)研究[J].中國免疫學(xué)雜志,2001; 17(5)∶249.
  19. 19. 陳農(nóng).胃癌患者手術(shù)前后外周血自然殺傷細(xì)胞和T淋巴細(xì)胞亞群的變化[J].浙江醫(yī)學(xué),2002; 24(10)∶579.
  20. 20. 董暉,王朝杰.結(jié)直腸癌患者免疫狀況與腫瘤分期的關(guān)系[J].國外醫(yī)學(xué)·放射醫(yī)學(xué)核醫(yī)學(xué)分冊,2005; 29(3)∶115.
  21. 21. 陳榮,蔡景理,周斌,等.免疫增強(qiáng)型腸內(nèi)營養(yǎng)制劑對結(jié)直腸腫瘤術(shù)后機(jī)體免疫的影響[J].中華胃腸外科雜志,2005; 8(4)∶328.